Related Experiment Video

Updated: May 13, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.8K

Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets

Francesco Rocco Bertuccio1,2, Simone Montini1,2, Maria Antonietta Fusco1,2

  • 1Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy.

Cancers
|April 14, 2025
PubMed
Abstract

Insights

Pleural mesothelioma (PM) is a rare cancer with poor prognosis. Research into its genetic landscape and novel therapeutic targets offers hope for improved treatment strategies and patient outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Pleural mesothelioma (PM) is an aggressive cancer linked to asbestos, genetics, and mutations.
  • Current treatments offer limited survival benefits, with a median of 6-18 months.

Purpose of the Study:

  • To review advancements in understanding PM's molecular and genetic basis.
  • To identify promising therapeutic targets and evaluate emerging clinical trial data.

Main Methods:

  • Comprehensive review of genetic and epigenetic alterations in PM.
  • Analysis of key signaling pathways implicated in PM development.
  • Examination of novel therapeutic targets and ongoing clinical trials.

Main Results:

  • Identification of numerous potential therapeutic targets.
  • Emerging clinical trials show promising efficacy for novel strategies.
  • Understanding of PM's genetic and epigenetic landscape is advancing.

Conclusions:

  • Novel therapeutic strategies targeting PM's molecular landscape are under investigation.
  • Precision medicine approaches hold potential for improving patient prognosis.
  • Continued research and clinical trials are crucial for advancing PM treatment.
Keywords:
actionable targetsgeneticspersonalized medicinepleural mesothelioma

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.7K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
163
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K